Dr. Beth Holder is a research associate at Imperial College London. She received her BSc (Hons) in Biomedical Science from The University of Manchester in 2007. During her degree, she spent a year at the MRC laboratories in The Gambia, investigating the effect of early-life EBV/CMV infection on infant vaccine responses. Her PhD, awarded in 2011, was based at The Maternal and Fetal Health Research Centre at The University of Manchester and Yale University School of Medicine. Upon completion of her PhD, Dr. Holder took up a postdoc at the Institute of Liver Studies at King’s College London, where she worked on a project to develop an antigen-specific regulatory T cell (Treg)-based therapy for treatment of autoimmune hepatitis. Dr. Holder has now returned to the field of maternal/infant health, and is currently working as a postdoctoral research associate in the Section of Paediatrics.
Dr. Holder has a long-standing interest in extracellular vesicle research. During her PhD, she investigated the effect of placental microvesicles and the Human Endogenous Retroviral (HERV) protein, syncytin 1, on maternal immune cells. Her current research is now focused on investigating the bi-directional trafficking of exosomes between the maternal immune system and the feto-placental unit.